Psychedelinks is a weekly digest of news, business, and culture in the psychedelics industry curated by members of Emerge Law Group’s groundbreaking Psychedelics Industry Group.
Decriminalization, Legalization, & Rescheduling Efforts
Petition language submitted to the state Tuesday would decriminalize the production of psychedelic mushrooms and other plants for people over the age of 18.
Two very different proposals could wind up on the state ballot.
A Seattle doctor specializing in end-of-life care filed a formal petition with the U.S. Drug Enforcement Administration (DEA) this week challenging the government’s Schedule I classification of psilocybin, the main psychoactive component of psychedelic mushrooms. The petition, dated Tuesday, request…
Lawmakers said they decided to slow down the process given COVID strain at the Department of Health, which would be tasked to create new rules regulating the medicine.
Oregon Psilocybin Services Act (M109)

Treating mental health conditions is a key component of the future of legal psilocybin services in Oregon. But businesses hoping to enter the marketplace are pressing state regulators to allow creative offerings, too.
Right To Try
A three-judge panel of the U.S. Court of Appeals for the Ninth Circuit has rejected a lawsuit by cancer patients and their doctor seeking access to psilocybin—the main psychoactive compound in psychedelic mushrooms—to help treat end-of-life depression and anxiety. The patients and Seattle-based pall…

Bipartisan Congressional support for allowing terminal patients to seek relief from anxiety and depression in alignment with ongoing international research on the effectiveness of psilocybin in mental health care Statement The Ninth Circuit’s opinion today, January 31, 2022, finding that the agency action in this matter was not final - “the DEA’s response letter was…

Bipartisan Congressional support for allowing terminal patients to seek relief from anxiety and depression in alignment with ongoing international research on the effectiveness of psilocybin in mental health care Statement Following issuance of the Ninth Circuit’s opinion in AIMS v DEA on Monday, January 31, 2022, finding lack of jurisdiction to review the DEA’s refusal to allow access…
Research, Therapy, & Science
A Utah House committee approved a bill on Thursday that would create a task force to study and make recommendations on the therapeutic potential of psychedelic drugs and possible regulations for their lawful use. The legislation, sponsored by Rep. Brady Brammer (R), passed the House Health and Human…
The free-spirited business leaders in the rapidly growing capital of Texas are wholeheartedly embracing opportunities for psychedelic research and therapy.
This could be the future treatment of mood disorders like depression.
Business
California-based “XR wellness and digital psychedelics platform” Tripp continues its acquisition path to growth with its acquisition of the world’s largest VR meditation community, EvolVR, following its purchase last year of PsyAssist, a mobile app used by people to keep their psy…
Subscribe
Subscribe to Psychedelinks to receive essential weekly articles on news, business, and culture in the psychedelics industry, delivered straight to your inbox.